Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Necrotic tissue damage as a result of Duchenne muscular dystrophy

PepGen focuses on the development of technology underpinning the peptide-mediated delivery of nucleic acid drugs and was spun out from the University of Oxford in 2018. PepGen’s technology platform was developed through a decade-long scientific collaboration between co-founders Professor Matthew Wood (Oxford) and Dr Michael Gait (MRC Laboratory of Molecular Biology).

The company received initial seed funding from Oxford Sciences Innovation (OSI) to focus on commercialisation of the technology platform for neuromuscular disease indications.

The full story is available on the PepGen website

 

Similar stories

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

Why we must expand newborn screening

Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.

Innovation award for Paediatrics researcher to develop new treatments for childhood cancer

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Professor Matthew Snape named NIHR Senior Investigator

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

Enriching Engagement (Round 2) awardees announced

The awardees for the second round of the University of Oxford’s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.

Featured publication: Advances in oligonucleotide drug delivery

Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.